Anakinra in children and adults with Still's disease. (26th November 2019)

• Record Type: Journal Article
• Authors: Vastert, Sebastiaan J; Jamilloux, Yvan; Quartier, Pierre; Ohlman, Sven; Osterling Koskinen, Lisa; Kullenberg, Torbjörn; Franck-Larsson, Karin; Fautrel, Bruno; de Benedetti, Fabrizio
• Is Part Of: Rheumatology. Volume 58(2019)Supplement 6
• Page Start: vi9
• Page End: vi22
• Publication Date: 2019-11-26
• Subjects: adult-onset Still's disease (AOSD) -- anakinra -- IL-1 -- IL-1 receptor antagonist (IL-1Ra) -- systemic juvenile idiopathic arthritis (sJIA) -- Still's disease; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/kez350
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Systemic juvenile idiopathic arthritis and adult-onset Still's disease are rare autoinflammatory disorders with common features, supporting the recognition of these being one disease—Still's disease—with different ages of onset. Anakinra was recently approved by the European Medicines Agency for Still's disease. In this review we discuss the reasoning for considering Still's disease as one disease and present anakinra efficacy and safety based on the available literature. The analysis of 27 studies showed that response to anakinra in Still's disease was remarkable, with clinically inactive disease or the equivalent reported for 23–100% of patients. Glucocorticoid reduction and/or stoppage was reported universally across the studies. In studies on paediatric patients where anakinra was used early or as first-line treatment, clinically inactive disease and successful anakinra tapering/stopping occurred in >50% of patients. Overall, current data support targeted therapy with anakinra in Still's disease since it improves clinical outcome, especially if initiated early in the disease course.